Excellent place to follow the path, difficult to create your own - Associate Principal Scientist bei Merck: Mitarbeiterbewertung

4,0
13. Jan. 2022
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

1) Solid science and thorough drug discovery and development process 2) World leader in immune-oncology and infectious disease. Future world leader in immunology and neuroscience. 3) Compensation seems to be industry average, but certain benefits relating to pension plan, housing assistance (in certain locations), and Inspire points program makes Merck stand out.

Kontras

1) Lack of Innovation. Although the company has made an effort over the past several years to address this, there is not enough of investment in innovation and several bureaucratic systems in place to prevent innovation. 2) Serious IT and data infrastructure problem. These archaic processes/systems will likely result in the company struggling to keep up with competitors in the digital era. 3) Difficult publishing research articles, which is not good for early career scientists trying to impact their respective fields.

Mehr Bewertungen zu Merck entdecken

5,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Excellent company to work with.

Kontras

No cons encountered so far

4,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Kontras

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Bewertungen anzeigen nach: Hilfreich|Sterne|Datum|Alle